Category Archives: Public Policy

Latest From Public Policy

Here are the Facts about the IPR Kill Rate


FiercePhrma recently ran an article repeating a dubious analysis of the crisis caused by the rapidly increasing number of biopharma related inter partes reviews (IPR) currently within the United States Patent and Trademark Office (PTO). It is troubling that in a single breath Ronny Gal both dismissed the biopharmaceutical industry’s concerns with the PTO’s IPR process and acknowledged that limited data prevents any firm conclusions about the potential impact of IPR on biotech innovation. If Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

102 Organizations Urge Congress to Maintain a Strong Patent System and Protect Innovation

US Capitol Building

A diverse group of more than 100 national and state-based advocacy organizations have united to urge Congress to preserve important patent protections that incentivize biopharmaceutical research necessary to innovate and develop new cures and treatments for serious diseases. In a letter sent to the Hill this week, these patient advocates asked Congress to amend the Innovation Act (H.R. 9) to preserve the highly-detailed and sophisticated systems designed by Hatch-Waxman and BPCIA and avoid weakening the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Congress Blog: Medical Advances Keep Me Running

U.S. Capitol Building - Congress

This week, 74-year-old multiple myeloma patient Don Wright shares his story on how cancer drugs have allowed him to not only keep his cancer in check, but enabled him to be well enough and free enough to run marathons around the country. For 12 years, Wright has been battling a cancer called multiple myeloma, a rare cancer in the bone marrow that used to have a life expectancy of just three years. Medical advances changed that. Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post

Register for the 2015 BIO IP & Diagnostics Symposium!

Biotechnology Industry Organization (BIO)

The Third Annual BIO IP & Diagnostics Symposium takes place on September 18, 2015 in Alexandria, Virginia! Have you reserved your seat at the Symposium yet? Space is limited. Register today. The symposium will bring together representatives of academia, government and industry to review the current patent law landscape and evaluate the impact on both the genetic diagnostics and biopharmaceutical sectors. The program will review IP issues for both diagnostics generally and companion diagnostics. It will Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , , ,

WSJ: U.S. Concessions on TPP Means Fewer Cures

Seal of the President of the U.S.

Today’s Wall Street Journal editorial, Pacific Trade Brinksmanship, does an outstanding job highlighting the important role that patent protection plays in promoting innovation and fostering medical breakthroughs. The article highlights why adequate protections for biologics must be a centerpiece of a successful Trans-Pacific Partnership (TPP). One of the issues being negotiated is the right amount of patent protection for innovative medicines. As the editorial notes, the U.S. currently wants “biologic protections to last a dozen Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,